Gambling.com Analysts Slash Their Forecasts Following Q2 Results - Gambling.com Gr (NASDAQ:GAMB)

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled therapy for pulmonary arterial hypertension (PAH). The Phase 1 trial will assess safety and pharmacokinetics in healthy volunteers. If successful, a Phase 2 trial in PAH patients is planned for 2027. UTHR stock closed at $591.20, down 0.28%.

Beneficient (BENF) filed in Delaware Chancery Court to invalidate ~$130M debt to HCLP and recover ~$211M paid. Success could remove the debt. This is part of BENF's plan to separate from Heppner-linked obligations after his May 2026 conviction.

Forward Air (FWRD) signed a 2-year deal with a major customer, retaining most services and expecting revenue to exceed 2025 levels in 2026–2028. The agreement includes a transition period for some services from Nov 2026 to Mar 2027, according to the company.

Beneficient (BENF) filed a motion in Delaware Court to invalidate HCLP debt, alleging fraud by former CEO Brad Heppner. The company seeks to eliminate the debt and separate from Heppner's interests, while pursuing a potential consensual resolution. Heppner was convicted in May 2026 for securities and wire fraud.

Wells Fargo reduced Hubbell's (HUBB) price target to $525 from $531, citing margin pressures and mixed Q3 results. The stock trades at $434 with a P/E of 25.6. Hubbell reported Q3 earnings of $5.91 per share, beating estimates, but guided Q4 below expectations due to cost pressures. The company expects 9% organic growth next year but faces margin challenges.

Wells Fargo raised its price target for Johnson Controls (JCI) to $200 from $186, citing strong Q4 results and growth outlook. JCI shares are up 31% YTD, trading near a 52-week high. The firm sees potential upside of more than $7, with sustainable growth drivers. JCI reported Q4 adjusted earnings of $1.59 per share and revenue of $7.11 billion, both exceeding estimates.